Vepugratinib

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Urinary Bladder NeoplasmsCarcinoma, Transitional Cell

20 competitors in Urinary Bladder Neoplasms

#DrugCompanyPhaseTrials

1

Gemzar

Johnson & Johnson

Phase 3

42

Imfinzi

AstraZeneca

Phase 3

33

Trexall

Jazz Pharmaceuticals

Phase 3

14

Velban

Eli Lilly

Phase 3

15

Adriamycin

Pfizer

Phase 3

16

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

37

Cetrelimab

Johnson & Johnson

Phase 3

38

Lynparza

AstraZeneca

Phase 2

19

TAR-200

Johnson & Johnson

Phase 3

310

Padcev

Pfizer

Phase 1

2Show 8 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Urinary Bladder Neoplasms3 trials

FORAY: A Phase 2, Randomized, Open-Label Study Evaluating Vepugratinib in Adults With FGFR3 Altered Low Grade, Intermediate Risk, Non-muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma

Not yet recruiting·Eli Lilly·Phase 2·NCT07827612·161 enrolled

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations

Recruiting·Eli Lilly·Phase 1·NCT05614739·677 enrolled

Expanded Access for Vepugratinib in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Available·Eli Lilly··NCT07675057

Carcinoma, Transitional Cell1 trial

FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration

Recruiting·Eli Lilly·Phase 3·NCT07218380·450 enrolled

Details

Drug Info

Related News